Home LiteratureArticle Details
PMID: 446506 Published · ppublish English Comparative Study Journal Article

Histological grading of transitional cell tumours of the bladder. Value of histological grading (WHO) in prognosis.

European urology ·Vol. 5 ·No. 5 ·1979-00-00 ·Pages 311-8

Collan Y, Mäkinen J, Heikkinen A

Abstract

Mortality among 139 patients with transitional cell tumour of the bladder was studied. Tumours were reevaluated according to the grading system recommended by WHO. The absolute 5-year survival of histologically benign papilloma cases was 68%, of grade I carcinoma cases 64%, of grade II carcinoma cases 42% and of grade III carcinoma patients 34%. Clinical staging (UICC), however, would have been more effective than histological grading (WHO) for prognostic purposes. 3 of the 14 patients with histologically benign papilloma in this study developed grade I carcinoma during follow-up periods of between 4.5 and 24 years. Following radical treatment all recurrences were papillomas. The study suggests that histological grading should be used to complement clinical staging in prognosis and that with half-yearly check-ups and elimination of any tumours thus detected, patients with papilloma rarely develop carcinomas of higher grade than grade I.

MeSH Terms
Aged Carcinoma, Papillary/mortality,pathology Carcinoma, Transitional Cell/mortality,pathology Female Follow-Up Studies Humans Male Middle Aged Prognosis Urinary Bladder/pathology Urinary Bladder Neoplasms/mortality,pathology World Health Organization
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Collan Y
Mäkinen J
Heikkinen A
Article Info
Journal
European urology
Abbr.
Eur Urol
ISSN
0302-2838
Published
1979-00-00
Pages
311-8
Language
English
Region
Switzerland
NLM ID
7512719
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com